secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-06-02T20:01:37+00:00
Accession:  0000950103-26-008321
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM
--------------------------------------------------------------------------------

- Approved increase in authorized shares under 2019 Equity Incentive Plan: 46.6M for, 18.9M against.
- Capital range expanded to CHF 10.4M lower / CHF 15.6M upper limit.
- Conditional share capital for financing increased from 38.0M to 48.0M shares.
- Board compensation capped at $2.5M; executive fixed $2.6M + variable $5.5M.
- All nine director nominees reelected; all 12 proposals passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-008321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer